197 related articles for article (PubMed ID: 33560717)
1. Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients.
Aksu A; Karahan Şen NP; Tuna EB; Aslan G; Çapa Kaya G
Nucl Med Commun; 2021 May; 42(5):503-509. PubMed ID: 33560717
[TBL] [Abstract][Full Text] [Related]
2. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. [
Xie Y; Li C; Zhang L; Zang S; Yu F; Wang S; Wang F
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1143-1148. PubMed ID: 36073212
[TBL] [Abstract][Full Text] [Related]
6. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
8. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
9. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL
J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of volumetric parameters based on
Li Y; Chen J; Wang X; Yang P; Yang J; Zhao Q; Li J
Front Oncol; 2024; 14():1335205. PubMed ID: 38469242
[TBL] [Abstract][Full Text] [Related]
11. Correlations between whole body volumetric parameters of
Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H
Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
[TBL] [Abstract][Full Text] [Related]
12. Utility of PSMA-PET derived volumetric parameters in initial risk stratification and prediction of prostate cancer metastasis - a head-to-head comparison of the radiotracers 18F-PSMA-1007 and 68Ga-PSMA-11.
Chandekar KR; Satapathy S; Singh H; Kumar R; Kumar S; Kakkar N; Mittal BR; Singh SK
Nucl Med Commun; 2024 Jun; ():. PubMed ID: 38932503
[TBL] [Abstract][Full Text] [Related]
13. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?
Karyağar S; Güven O; Karyağar SS; Arici S; Selvi O; Geredeli Ç; Özülker F
Nucl Med Commun; 2021 Sep; 42(9):1011-1016. PubMed ID: 33958536
[TBL] [Abstract][Full Text] [Related]
14.
Dong S; Li Y; Chen J; Li Y; Yang P; Li J
Front Oncol; 2022; 12():1025930. PubMed ID: 36568229
[TBL] [Abstract][Full Text] [Related]
15. The Role of 68GA-PSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy.
Gultekin MH; Demirci E; Turegun FA; Kabasakal L; Sahin OE; Ocak M; Onal B; Erozenci A
Urol J; 2020 Dec; 18(1):58-65. PubMed ID: 33349912
[TBL] [Abstract][Full Text] [Related]
16.
Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
[TBL] [Abstract][Full Text] [Related]
17. Predictive significance of intraprostatic volumetric parameters derived from early and standard time 68Ga-PSMA PET/CT images in newly diagnosed prostate cancer patients.
Erdogan EB; Tekce E; Koca S; Aslan N; Toluk O; Aydin M
Nucl Med Commun; 2024 Jul; 45(7):629-641. PubMed ID: 38835183
[TBL] [Abstract][Full Text] [Related]
18. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
[TBL] [Abstract][Full Text] [Related]
19. Correlations of the
Karyagar SS; Karyagar S; Guven O
Hell J Nucl Med; 2020; 23(2):120-124. PubMed ID: 32716402
[TBL] [Abstract][Full Text] [Related]
20. Correlations of
Topuz ÖV; Aksu A; Erinç SR; Tamam MÖ
Hell J Nucl Med; 2021; 24(1):60-65. PubMed ID: 33866340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]